Publications by authors named "G E Newby"

Background: Global progress toward malaria elimination and eradication goals has stagnated in recent years, with many African countries reporting increases in malaria morbidity and mortality. Insecticide-treated nets and indoor residual spraying are effective, but the emergence and increased intensity of insecticide resistance and the challenge of outdoor transmission are undermining their impact. New tools are needed to get back on track towards global targets.

View Article and Find Full Text PDF

Prion disease is a fatal neurodegenerative disease caused by the misfolding of prion protein (PrP) encoded by the PRNP gene. While there is currently no cure for the disease, depleting PrP in the brain is an established strategy to prevent or stall templated misfolding of PrP. Here we developed in vivo cytosine and adenine base strategies delivered by adeno-associated viruses to permanently modify the PRNP locus to achieve PrP knockdown in the mouse brain.

View Article and Find Full Text PDF

Delivering ribonucleoproteins (RNPs) for in vivo genome editing is safer than using viruses encoding for Cas9 and its respective guide RNA. However, transient RNP activity does not typically lead to optimal editing outcomes. Here we show that the efficiency of delivering RNPs can be enhanced by cell-penetrating peptides (covalently fused to the protein or as excipients) and that lipid nanoparticles (LNPs) encapsulating RNPs can be optimized for enhanced RNP stability, delivery efficiency and editing potency.

View Article and Find Full Text PDF

Rhodopsin, the prototypical class-A G-protein coupled receptor, is a highly sensitive receptor for light that enables phototransduction in rod photoreceptors. Rhodopsin plays not only a sensory role but also a structural role as a major component of the rod outer segment disc, comprising over 90% of the protein content of the disc membrane. Mutations in which lead to structural or functional abnormalities, including the autosomal recessive E150K mutation, result in rod dysfunction and death.

View Article and Find Full Text PDF
Article Synopsis
  • Researchers successfully corrected the sickle cell mutation in hematopoietic stem cells (HSCs) using a technique called in vivo base editing, transforming the sickle mutation into a benign variant.
  • The method involved creating adenoviral vectors that effectively delivered the editing tool, resulting in a 35% conversion rate of the mutation in lab settings and 88% in a mouse model.
  • The treated mice showed no side effects and improved disease symptoms, indicating that this approach could be a practical treatment option for sickle cell disease, especially in areas with limited resources.
View Article and Find Full Text PDF